CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 420 enrolled
Drug / intervention
Olumacostat Glasaretil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02431052
NCT02431052Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris

Dermira, Inc.·interventional·Posted Apr 30, 2015·Updated Jul 20, 2021

In Brief

A Phase 2 clinical trial evaluating Olumacostat Glasaretil and Vehicle for Acne Vulgaris. Completed, enrolled 420 participants across 34 sites in 2 countries.

Detailed Summary

The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 30, 2015
Enrollment StartApr 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.2 years ago

Interventions

Olumacostat Glasaretildrug

Vehicleother